April 25, 2018 / 12:33 PM / in 7 months

BRIEF-Alder Biopharmaceuticals - New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals In Patients With Episodic Migraine

April 25 (Reuters) - Alder Biopharmaceuticals Inc:

* ALDER BIOPHARMACEUTICALS® NEW DATA DEMONSTRATED EPTINEZUMAB INCREASED MIGRAINE-FREE INTERVALS (UP TO 32.5 DAYS) AND IMPROVED QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH EPISODIC MIGRAINE

* ALDER BIOPHARMACEUTICALS INC - IN TRIAL, PATIENTS EXPERIENCED A SIGNIFICANT REDUCTION IN MIGRAINE DAYS AND IMPROVED QUALITY-OF-LIFE OUTCOMES

* ALDER BIOPHARMA- IN POST HOC ANALYSIS, PATIENTS ACHIEVING A 75 PERCENT OR GREATER RESPONSE RATE HAD OVER AN 8-FOLD INCREASE IN DAYS BETWEEN MIGRAINES

* ALDER BIOPHARMACEUTICALS INC - 29.7 PERCENT OF PATIENTS ACHIEVED A 75 PERCENT OR GREATER REDUCTION IN MIGRAINE DAYS FROM BASELINE

* ALDER BIOPHARMACEUTICALS INC - OBSERVED SAFETY PROFILE FOR PROMISE 1, TO DATE, IS CONSISTENT WITH PREVIOUSLY REPORTED EPTINEZUMAB STUDIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below